Interesting quarterly, a little underwhelming from a revenue point of view however plenty of reasons to buy and hold.
Capacity is now at 1.3M a month for Pascal plus 300K for Galileo.
Considering they only sold c.800K units for the whole quarter, and by looking at the expenditure it looks like Atomo are building a stockpile for a larger order.
If Atomo were selling through their entire inventory, revenue would be close to $17M a quarter (at $3.50 per device).
Elion platform launch imminent which will open additional diseases and revenue streams. Access Bio deal alone will soak up 600K units a quarter to reach their take or pay deal commitment.
No mention of DIVOC or Indian approval, so that deal must have fallen by the wayside.
Interesting quarterly, a little underwhelming from a revenue...
Add AT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.10M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.1¢ | 2.0¢ | $1.244K | 61.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 1627919 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 152000 | 2 |
View Market Depth
| Last trade - 15.45pm 09/09/2024 (20 minute delay) ? |
| AT1 (ASX) Chart |